CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.

CalciMedica, Inc.

CalciMedica is developing therapeutics that inhibit CRAC channels to address life-threatening inflammatory diseases affecting the pancreas, kidney, and lung.

CalciMedica

CalciMedica | 1,134 followers on LinkedIn. Leader in the development of CRAC channel inhibitor drugs for inflammatory diseases | CalciMedica is a privately held, clinical stage biotechnology company with a platform focused on CRAC channel drug discovery and development for the treatment of acute and severe inflammatory diseases. The Company was founded in 2007 by Ken Stauderman, CalciMedica’s Chief Scientific Officer, and colleagues at Torrey Pines Therapeutics in San Diego and Harvard’s Center for Blood Research in Cambridge, MA. Dr.

Frederic Guerard

Founder and Managing Director at Danforth Advisors

Daniel Geffken

Chief Regulatory Officer CalciMedica

Raven Jaeger

SVP, Clinical Development at CalciMedica

Andrew Cunningham

We are delighted to welcome Stephen Bardin to the CalciMedica team as Chief Financial Officer, and look forward to working together as we continue to advance our clinical-stage pipeline. Read the press release: https://lnkd.in/excRjSrX

We are excited to be presenting the full data set from our Phase 2b CARPO trial of Auxora in #acutepancreatitis on a conference call and webcast, during which Prof. Robert Sutton will deliver his plenary presentation from the American College of Gastroenterology (ACG) Annual Scientific Meeting. See our press release for a description of the late-breaking, positive data, including a win ratio analysis, and for instructions to join the webcast: https://lnkd.in/eqDePnKK

We are pleased to announce a late-breaking abstract for a plenary presentation by Prof. Robert Sutton from the University of Liverpool at American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. Details in the press release: https://lnkd.in/egniHv87 #ACG2024

Earlier this week we shared the news that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe acute kidney injury with associated acute hypoxemic respiratory failure (AHRF). There are currently no approved therapies for AKI and we look forward to continuing to evaluate Auxora as a potential treatment for this severe and underserved disease. See our press release: https://lnkd.in/e8HzWKjJ

Today we announced that the first patient has been dosed in #KOURAGE , our Phase 2 trial evaluating Auxora for the treatment of severe #acutekidneyinjury with associated acute hypoxemic respiratory failure (AHRF). We expect to share topline data from this trial in 2025. Read the press release: https://lnkd.in/eRmNxsik

We are excited to share that today we announced positive topline data from our Phase 2b CARPO trial of #Auxora in #acutepancreatitis (AP). The trial established a dose response for Auxora across multiple endpoints, identified both the target patient population and the likely drug dose for a pivotal trial, and re-affirmed Auxora’s safety profile and tolerability as seen in prior clinical trials. Read the press release: https://lnkd.in/gAgBCaAW

We recently completed enrollment in our ongoing Phase 2b clinical trial, CARPO, which is evaluating Auxora™ in patients with #acutepancreatitis with accompanying SIRS. For details on the clinical trial, visit https://lnkd.in/eTwrEFCa , or hear some of our study investigators discuss the potential for #Auxora to improve outcomes for patients with AP.

Today we announced that the last patient has been enrolled in our Phase 2b CARPO trial of Auxora™ in #acutepancreatitis (AP). Details here: https://lnkd.in/eqjarCww

Today CalciMedica reported financial results for the year ended December 31, 2023. Read the press release here: https://lnkd.in/eEFNhNSK

Yesteday we presented data from preclinical studies of Auxora in acute kidney injury at the 29th International AKI & CRRT Conference. The data show that Auxora hastens recovery of kidney function and improves survival in a rat model of #AKI . https://lnkd.in/g5h4vxbY

	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	2.52M -	4.64M 83.75%	2.51M 45.79%	527K 79.03%	1.72M 225.62%	1.42M 17.31%
accumulated other comprehensive income loss		3K -	-4K 233.33%	-16K 300%	-37K 131.25%	2K 105.41%
cash and cash equivalents	12.83M -	15.87M 23.66%	33.42M 110.57%	13.36M 60.01%	17.30M 29.48%	5.53M 68.04%
cash and short term investments	12.83M -	35.96M 180.16%	95.03M 164.30%	63.67M 33.00%	39.13M 38.55%	11.24M 71.28%
common stock			2K -	2K 0%	2K 0%	1K 50%
deferred revenue					1.02M -
deferred revenue non current
deferrred tax liabilities non current
goodwill
goodwill and intangible assets
intangible assets
inventory					-39K -
long term debt
long term investments
net debt	-12.83M -	-15.87M 23.66%	-33.42M 110.57%	-13.36M 60.01%	-17.10M 27.96%	-5.53M 67.66%
net receivables					39K -
other assets
other current assets	611K -	315K 48.45%	4.21M 1,235.56%	3.41M 18.99%	542K 84.10%	367K 32.29%
other current liabilities	3.27M -	7.62M 132.80%	4.48M 41.12%	3.53M 21.28%	1.78M 49.58%	2.61M 46.57%
other liabilities
other non current assets	2.85M -	2.41M 15.39%	608K 74.81%	29K 95.23%		413K -
other non current liabilities			11K -	8K 27.27%
othertotal stockholders equity	2.01M -	2.88M 43.45%	228.16M 7,824.80%	234.22M 2.66%	240.80M 2.81%	154.22M 35.96%
preferred stock	78.81M -	131.36M 66.68%
property plant equipment net	1.51M -	1.98M 30.36%	1.95M 1.47%	1.98M 1.80%		167K -
retained earnings	-68.80M -	-105.84M 53.83%	-133.37M 26.01%	-169.19M 26.86%	-204.79M 21.04%	-146.06M 28.68%
short term debt					203K -
short term investments		20.09M -	61.62M 206.76%	50.31M 18.35%	21.82M 56.62%	5.71M 73.85%
tax assets
tax payables						77K -
total assets	17.81M -	40.66M 128.26%	101.79M 150.35%	69.09M 32.13%	39.67M 42.58%	12.19M 69.28%
total current assets	13.45M -	36.27M 169.77%	99.24M 173.61%	67.08M 32.41%	39.67M 40.86%	11.61M 70.75%
total current liabilities	5.79M -	12.25M 111.44%	7.00M 42.89%	4.06M 42.02%	3.70M 8.82%	4.03M 8.89%
total debt					203K -
total investments		20.09M -	61.62M 206.76%	50.31M 18.35%	21.82M 56.62%	5.71M 73.85%
total liabilities	5.79M -	12.25M 111.44%	7.01M 42.80%	4.07M 41.99%	3.70M 9.00%	4.03M 8.89%
total liabilities and stockholders equity	17.81M -	40.66M 128.26%	101.79M 150.35%	69.09M 32.13%	39.67M 42.58%	12.19M 69.28%
total non current assets	4.37M -	4.39M 0.48%	2.55M 41.81%	2.01M 21.30%		580K -
total non current liabilities			11K -	8K 27.27%
total stockholders equity	12.02M -	28.41M 136.37%	94.79M 233.65%	65.02M 31.40%	35.97M 44.68%	8.16M 77.32%

COM:CALCIMEDICA

CalciMedica

Last Close

3.45

22/11 21:00

Market Cap

49.23M

Beta: -

Volume Today

27.23K

Avg: -

Preview